Nothing Special   »   [go: up one dir, main page]

BR112014029573A2 - fármaco para a prevenção e/ou tratamento de doença renal policística - Google Patents

fármaco para a prevenção e/ou tratamento de doença renal policística

Info

Publication number
BR112014029573A2
BR112014029573A2 BR112014029573A BR112014029573A BR112014029573A2 BR 112014029573 A2 BR112014029573 A2 BR 112014029573A2 BR 112014029573 A BR112014029573 A BR 112014029573A BR 112014029573 A BR112014029573 A BR 112014029573A BR 112014029573 A2 BR112014029573 A2 BR 112014029573A2
Authority
BR
Brazil
Prior art keywords
drug
kidney disease
polycystic kidney
prevention
treatment
Prior art date
Application number
BR112014029573A
Other languages
English (en)
Inventor
Fujiki Hiroyuki
Aihara Miki
Kinoshita Shizuo
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of BR112014029573A2 publication Critical patent/BR112014029573A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/31Somatostatins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

resumo patente de invenção: "fármaco para a prevenção e/ou tratamento de doença renal policística". a presente invenção tem como objetivo proporcionar um fármaco de combinação que tem efeitos preventivos e/ou terapêuticos notavelmente excelentes sobre doença renal policística. a presente invenção proporciona um fármaco para a prevenção e/ou tratamento de doença renal policística, o qual compreende uma combinação de tolvaptan ou um profármaco do mesmo com um derivado de somatostatina, e um método para o tratamento de doença renal policística usando esse fármaco.
BR112014029573A 2012-05-31 2013-05-30 fármaco para a prevenção e/ou tratamento de doença renal policística BR112014029573A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261653524P 2012-05-31 2012-05-31
PCT/JP2013/065637 WO2013180310A1 (en) 2012-05-31 2013-05-30 Drug for preventing and/or treating polycystic kidney disease

Publications (1)

Publication Number Publication Date
BR112014029573A2 true BR112014029573A2 (pt) 2017-06-27

Family

ID=48670042

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014029573A BR112014029573A2 (pt) 2012-05-31 2013-05-30 fármaco para a prevenção e/ou tratamento de doença renal policística

Country Status (31)

Country Link
US (8) US9636382B2 (pt)
EP (1) EP2854815B1 (pt)
JP (4) JP6116591B2 (pt)
KR (2) KR102127180B1 (pt)
CN (2) CN107625953A (pt)
AR (1) AR091205A1 (pt)
AU (3) AU2013268343B2 (pt)
BR (1) BR112014029573A2 (pt)
CA (1) CA2873365A1 (pt)
CO (1) CO7160102A2 (pt)
CY (1) CY1120490T1 (pt)
DK (1) DK2854815T3 (pt)
EA (1) EA036062B1 (pt)
ES (1) ES2654768T3 (pt)
HK (1) HK1206992A1 (pt)
HR (1) HRP20180040T1 (pt)
HU (1) HUE035158T2 (pt)
IL (2) IL235623A0 (pt)
LT (1) LT2854815T (pt)
MX (1) MX366121B (pt)
MY (1) MY174625A (pt)
NO (1) NO2888775T3 (pt)
NZ (1) NZ630118A (pt)
PH (2) PH12018501227B1 (pt)
PL (1) PL2854815T3 (pt)
PT (1) PT2854815T (pt)
SG (2) SG10201609250QA (pt)
SI (1) SI2854815T1 (pt)
TW (2) TWI704919B (pt)
WO (1) WO2013180310A1 (pt)
ZA (1) ZA201408411B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009294320B2 (en) 2008-09-17 2015-04-16 Amryt Endo, Inc. Pharmaceutical compositions and related methods of delivery
TWI704919B (zh) * 2012-05-31 2020-09-21 日商大塚製藥股份有限公司 用於預防及/或治療多囊性腎臟病之藥物
WO2014104412A1 (en) * 2012-12-28 2014-07-03 Otsuka Pharmaceutical Co., Ltd. Injectable depot formulation comprising optically active tolvaptan and process of producing the same
TW201605488A (zh) * 2013-10-15 2016-02-16 大塚製藥股份有限公司 用以預防及/或治療多囊腎病之藥物
MA41462A (fr) 2015-02-03 2021-05-12 Chiasma Inc Méthode de traitement de maladies
CA3011982A1 (en) * 2016-01-21 2017-07-27 Chiasma Inc. Oral octreotide for the treatment of disease
WO2019118272A1 (en) * 2017-12-11 2019-06-20 Mayo Foundation For Medical Education And Research Using probenecid to treat polycystic kidney disease
GB201905711D0 (en) * 2019-04-24 2019-06-05 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases
JP2022543513A (ja) 2019-08-14 2022-10-13 オートディン シス インコーポレイテッド アクセルペダル及びブレーキペダルと連動するクラッチシステム
EP3916259B1 (en) 2019-10-16 2023-10-25 Autodyn Sys Inc. Rotary shaft assembly having novel structure
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
US20230158041A1 (en) * 2021-11-22 2023-05-25 Otsuka Pharmaceutical Co.,Ltd. Methods and compositions for treating autosomal dominant polycystic kidney disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0450097T3 (da) 1989-10-20 1996-05-20 Otsuka Pharma Co Ltd Benzoheterocykliske forbindelser
JP4154765B2 (ja) 1998-09-28 2008-09-24 ダイキン工業株式会社 天井取付型の空気吹出器
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
AR044852A1 (es) * 2003-06-24 2005-10-05 Novartis Ag Una composicion farmaceutica para la administracion parenteral que comprende un analogo de somatostatina
MY146042A (en) 2005-12-27 2012-06-15 Otsuka Pharma Co Ltd Water-soluble benzoazepine compound and its pharmaceutical composition
GB0602639D0 (en) 2006-02-09 2006-03-22 Novartis Ag Organic compounds
JP2009532346A (ja) 2006-03-31 2009-09-10 イラスマス・ユニバーシティ・メディカル・センター・ロッテルダム 腫瘍増殖制御のための新規組成物
CN101460170A (zh) * 2006-06-08 2009-06-17 诺瓦提斯公司 促生长素抑制素类似物同多巴胺或同促生长素受体拮抗物的组合
TWI459947B (zh) 2007-06-26 2014-11-11 Otsuka Pharma Co Ltd 苯并氮呯化合物及藥學製劑
TWI704919B (zh) 2012-05-31 2020-09-21 日商大塚製藥股份有限公司 用於預防及/或治療多囊性腎臟病之藥物

Also Published As

Publication number Publication date
AU2013268343A1 (en) 2014-11-27
NZ630118A (en) 2016-07-29
US20220241293A1 (en) 2022-08-04
HRP20180040T1 (hr) 2018-02-09
ZA201408411B (en) 2016-09-28
US20150141338A1 (en) 2015-05-21
EA201492279A1 (ru) 2015-05-29
JP2019001801A (ja) 2019-01-10
PH12018501227B1 (en) 2023-03-10
MX366121B (es) 2019-06-27
AU2013268343B2 (en) 2017-06-01
CN104334176B (zh) 2018-01-02
MY174625A (en) 2020-05-03
US9669075B2 (en) 2017-06-06
US20170196877A1 (en) 2017-07-13
EP2854815B1 (en) 2017-11-22
CA2873365A1 (en) 2013-12-05
NO2888775T3 (pt) 2018-08-04
LT2854815T (lt) 2018-02-12
DK2854815T3 (en) 2018-01-22
JP2017110029A (ja) 2017-06-22
US11957691B2 (en) 2024-04-16
KR102127180B1 (ko) 2020-06-29
US20190117666A1 (en) 2019-04-25
CY1120490T1 (el) 2019-07-10
PH12014502558A1 (en) 2015-01-21
US9636382B2 (en) 2017-05-02
US20170239265A1 (en) 2017-08-24
WO2013180310A1 (en) 2013-12-05
AU2019202158A1 (en) 2019-04-18
JP6724085B2 (ja) 2020-07-15
KR20150016597A (ko) 2015-02-12
US20240216389A1 (en) 2024-07-04
JP6938705B2 (ja) 2021-09-22
IL253441A0 (en) 2017-09-28
EP2854815A1 (en) 2015-04-08
JP2015517974A (ja) 2015-06-25
AU2017202757A1 (en) 2017-05-18
CO7160102A2 (es) 2015-01-15
PT2854815T (pt) 2017-12-20
PH12018501227A1 (en) 2020-09-14
TWI633887B (zh) 2018-09-01
SG10201609250QA (en) 2016-12-29
SG11201407368VA (en) 2015-01-29
TW201827056A (zh) 2018-08-01
IL235623A0 (en) 2015-01-29
PL2854815T3 (pl) 2018-03-30
US11013746B2 (en) 2021-05-25
US11147821B2 (en) 2021-10-19
SI2854815T1 (en) 2018-02-28
EA036062B1 (ru) 2020-09-22
KR102211354B1 (ko) 2021-02-03
CN104334176A (zh) 2015-02-04
KR20200034811A (ko) 2020-03-31
ES2654768T3 (es) 2018-02-15
HK1206992A1 (en) 2016-01-22
TW201400118A (zh) 2014-01-01
TWI704919B (zh) 2020-09-21
CN107625953A (zh) 2018-01-26
AU2019202158B2 (en) 2020-06-25
JP6116591B2 (ja) 2017-04-19
MX2014014476A (es) 2015-02-12
US20160058841A1 (en) 2016-03-03
AR091205A1 (es) 2015-01-21
PH12014502558B1 (en) 2015-01-21
US20190374549A1 (en) 2019-12-12
JP2020117535A (ja) 2020-08-06
HUE035158T2 (hu) 2018-05-02

Similar Documents

Publication Publication Date Title
BR112014029573A2 (pt) fármaco para a prevenção e/ou tratamento de doença renal policística
BR112014021498A2 (pt) composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado
BR112015007778A2 (pt) profármacos neutralizantes de vegf para o tratamento de condições oculares
BR112014021104A2 (pt) métodos e composições para o tratamento da doença de huntington
CR20120202A (es) Métodos y composiciones para tratar cáncer
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
BR112018004620A2 (pt) moduladores da expressão de kras
NI201000105A (es) Régimen de dosificación asociado con ésteres de paliperidona inyectables de acción prolongada.
GT201200220A (es) Ciertas triazolopiridinas y triazolopirazinas, composiciones de estas y sus métodos de empleo
MX2019003249A (es) Diagnostico, prevencion y tratamiento de enfermedades de la articulacion.
ECSP10010042A (es) Compuestos y composiciones como moduladores de la actividad de gpr119
BR112015022998A2 (pt) composições melhoradas para o tratamento de distrofia muscular
BR112015000150A2 (pt) composições farmacêuticas dissuasoras de abuso de liberação controlada
EA201590655A1 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
BR112014030386A2 (pt) compostos e composições para modular a atividade de egfr
BR112015004501A2 (pt) derivado de ácido hialurônico tendo aminoácidos e grupos esterila introduzidos no mesmo
BR112015016466A2 (pt) método para o tratamento de câncer baseado no estado de mutação de k-ras
BR112014019399A2 (pt) métodos de tratamento da fibrose
EA201200098A1 (ru) Конденсированные имидазолы и содержащие их композиции, предназначенные для лечения паразитарных заболеваний, таких как, например, малярия
DOP2007000053A (es) Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
BR112014031866A2 (pt) Composição farmacêutica intramamária para utilização no tratamento ou prevenção da mastite em um mamífero não humano e composição farmacêutica de fosfomicina e de pelo menos um anti-microbiano
BR112012009121A2 (pt) Novas composições para a prevenção e/ou tratamento de distúrbios degenerativos do sistema nervoso central
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112015015509A2 (pt) composto farmacêutico para a prevenção e tratamento de uma doença ou desordem cognitiva, neuro degenerativa ou doença neuronal

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]